Clinical trials: Choroid Diseases
Uveitis, Uveitis, Posterior
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of…
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- NCT02952001
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 16 sites in United States, India
- Volunteers
- 33 people
- Sponsor
- Clearside Biomedical, Inc.
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Healthy
Oat Phenolics Bioavailability
A diet rich in whole grain is inversely associated with cardiovascular disease risk and this benefit could be partly attributed to the phenolic acid content of whole grains.
- Trial name
- NCT02574039
- Testing
- Oat bran, refined grain
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Reading
Idiopathic Polypoidal Choroidal Vasculopathy
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal…
- Trial name
- NCT02397954
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ophthotech Corporation
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Treatment Of Radiation Retinopathy Trial
The purpose of this study is to demonstrate a statistically significant improvement of visual acuity after treatment using either Lucentis® or Triamcinolone® compared to no treatment, in patients with radiation retinopathy.
- Trial name
- TORR (NCT00811200)
- Testing
- ranibizumab, triamcinolone acetonide
- Volunteers
- 220 people
- Sponsor
- Leiden University Medical Center
Diabetic Macular Edema
Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema
The purpose of this clinical investigation is to evaluate the safety and tolerability of using the Oxulumis® microcatheterization device to administer Triesence® to the suprachoroidal space in participants with DME.
- Trial name
- NCT05172401
- Testing
- Oxulumis® suprachoroidal microcatheterization administration of Triesence®
- Sponsor
- Oxular Limited
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT01413191
- Testing
- Cixutumumab, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
- Trial name
- NCT05907954
- Testing
- Darovasertib
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells.
- Trial name
- NCT00398073
- Testing
- mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hyperoxemia, Cerebrovascular Circulation
HYPER MIND - Hyperoxia Effects on Cerebral Hemodynamics
This study aims to better understand how short periods of exposure to high oxygen levels affect blood flow in the brain of patients who are intubated and mechanically ventilated in the Intensive Care Unit (ICU).
- Conditions
- Hyperoxemia, Cerebrovascular Circulation, Cerebral Autoregulation, Critical Illness
- Trial name
- HYPER-MIND (NCT07377162)
- Testing
- Normobaric Hyperoxic Stimulus (NBHO)
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Erasme University Hospital
Myopia, Progressive, Choroid Disease
Choroidal Change on OCTA in Eyes With High Myopia
Myopia is a global healthy concern, especially the high myopia and pathological myopia among Asian populations. However, its mechanism still remains largely unclear.
- Trial name
- NCT04255524
- Testing
- Optic coherence tomography angiography (OCTA)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Choroidal Neovascularization, Uveitis
Conbercept in Choroidal Neovascularization Secondary to Uveitis
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis with Conbercept.
- Trial name
- NCT02934841
- Testing
- Conbercept
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Angioid Streaks, Choroidal Neovascularization
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
- Trial name
- NCT00599820
- Testing
- Intravitreal Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Age Related Macular Degeneration, Choroidal Neovascularization
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence…
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
- Trial name
- NCT00729846
- Testing
- Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- California Retina Consultants